Colleyville, TX, March 03, 2013 --(PR.com
)-- Heart Test Laboratories, developer of the MyoVista Heart screening device, is pleased to announce the transition from product development to manufacturing. Based on the results of clinical studies involving 40 beta units over the past two years, a final configuration of the MyoVista, hardware and software, has been established. The clinical experience during this time confirmed the efficacy of the technology and also lead to the incorporation of an additional screening tool. This added feature provides the clinician with a quantitative measure of ventricular function along with the initial observations concerning the detection of any abnormalities, if present. As a result of this addition, the computational requirements of the system increased dictating the need for a change in the electronic platform.The production version contains this enhanced unit intelligence.
Manufacturing of the MyoVista includes the delivery and technical assistance of certain key suppliers. This requires the integration of their production schedules with those of the company. The resulting forecast is dependent on those outside tasks conforming to a specific timetable.
Shipments are expected to commence in the latter half of the second quarter, 2013. These first shipments of MyoVista units will satisfy orders which have been placed in 2012.
Please contact Heart Test Labs with any questions you may have.